Update shared on15 Aug 2025
With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00.
What's in the News
- Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.
- OGM enabled identification of NKX2 family gene rearrangements in 33% of young T-ALL cases, previously uncharacterized in this age group, revealing genotype-based survival outcomes and streamlining profiling into a single workflow.
- Bionano released updated VIA and Solve software featuring AI-driven OGM data analysis, continuous learning from lab interpretation history, improved phenotype scoring, expanded control variant databases, and better sensitivity/specificity.
- Stratys Compute server upgrades enabled up to 2x cancer sample throughput and expanded pipeline support by leveraging advanced GPU technology.
Valuation Changes
Summary of Valuation Changes for Bionano Genomics
- The Consensus Analyst Price Target remained effectively unchanged, at $9.00.
- The Future P/E for Bionano Genomics remained effectively unchanged, at 6.20x.
- The Discount Rate for Bionano Genomics remained effectively unchanged, at 10.51%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.